| Soliris (eculizumab) / AstraZeneca |
| Available | N/A | | NA | Eculizumab | Hudson Medical | Coronavirus | | | | |
NCT04355494: SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 |
|
|
| No Longer Available | N/A | | Europe, US | eculizumab, Soliris | Alexion Pharmaceuticals | COVID-19, Pneumonia, Viral, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | | | | |
| No Longer Available | N/A | | NA | Eculizumab, Soliris, monoclonal antibody | Alexion Pharmaceuticals | Covid19 | | | | |
NAP, NCT04671810: Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria® |
|
|
| Completed | N/A | 44 | RoW | Elizaria®, Eculizumab | AO GENERIUM | Paroxysmal Nocturnal Hemoglobinuria | 12/22 | 05/23 | | |
| Available | N/A | | NA | Danicopan, ALXN2040 | Alexion Pharmaceuticals, Inc. | Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis | | | | |
| Not yet recruiting | N/A | 11 | RoW | | AstraZeneca | Observational | 10/24 | 10/24 | | |
m-TMA, NCT06098378: Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab |
|
|
| Recruiting | N/A | 30 | Europe | | University Hospital, Strasbourg, France | Thrombotic Microangiopathies | 06/25 | 06/25 | | |
ChiCTR2300067949: The real world study of Eculizumab for paroxysmal nocturnal hemoglobinuria treatment in China |
|
|
| Not yet recruiting | N/A | 10 | | Eculizumab | West China Hospitai, Sichuan University; West China Hospitai, Sichuan University, Apply for hospital project funds | paroxysmal nocturnal hemoglobinuria | | | | |
